Transaction #12104 · Form 4 · 0001437749-25-036125
FILANA THERAPEUTICS, INC. · Purchase · Common Stock
FILANA THERAPEUTICS, INC. · Transacted November 20, 2025 · Filed November 24, 2025
What does this filing report?
An SEC Form 4 filing for FILANA THERAPEUTICS, INC. records a purchase involving Common Stock on November 20, 2025. The reported quantity was 150,000. The filing date is November 24, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- FILANA THERAPEUTICS, INC.
- Company CIK
- 0001069530
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 150,000
- Reported price
- 2.76 · See footnotes
- Reference value
- 414,000
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 938,060
- Ownership description
- By Trust
- SEC acceptance time
- Nov 24, 2025, 4:02 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Barry Richard ↗
President & CEO · Director
CIK 0001562371
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Filing footnotes & remarks
- F1
- The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple open market transactions at prices ranging from $2.74 to $2.80 per share. The reporting person undertakes to provide to Cassava, any security holder of Cassava or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.